HPC Biosciences (HPBL) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2025Income Metrics
Revenue
4.6B
Gross Profit
1.3B
27.82%
Operating Income
279.4M
6.03%
Net Income
133.3M
2.88%
Balance Sheet Metrics
Total Assets
2.8B
Total Liabilities
2.0B
Shareholders Equity
791.6M
Debt to Equity
2.49
Cash Flow Metrics
Operating Cash Flow
-266.4M
Free Cash Flow
-188.3M
Revenue & Profitability Trend
HPC Biosciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.6B | 2.9B | 3.5B | 1.1B | 156.6M |
| Cost of Goods Sold | 3.3B | 2.5B | 3.1B | 962.7M | 145.4M |
| Gross Profit | 1.3B | 370.6M | 429.7M | 151.0M | 11.2M |
| Operating Expenses | 727.5M | 64.8M | 78.0M | 27.3M | 5.4M |
| Operating Income | 279.4M | 94.5M | 105.6M | 4.7M | -54.4M |
| Pre-tax Income | 179.8M | 2.0M | 11.8M | -31.6M | 435.3M |
| Income Tax | 46.5M | -1.1M | 4.2M | -7.1M | -200.9M |
| Net Income | 133.3M | 3.1M | 7.6M | -24.5M | 636.2M |
| EPS (Diluted) | - | -₹0.37 | -₹1.06 | -₹2.98 | ₹65.80 |
Income Statement Trend
HPC Biosciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.7B | 1.2B | 785.6M | 599.2M | 121.0M |
| Non-Current Assets | 1.1B | 1.2B | 1.2B | 1.1B | 602.6M |
| Total Assets | 2.8B | 2.3B | 2.0B | 1.7B | 723.6M |
| Liabilities | |||||
| Current Liabilities | 1.6B | 1.2B | 832.8M | 459.1M | 80.4M |
| Non-Current Liabilities | 359.8M | 487.9M | 522.8M | 908.0M | 380.1M |
| Total Liabilities | 2.0B | 1.7B | 1.4B | 1.4B | 460.5M |
| Equity | |||||
| Total Shareholders Equity | 791.6M | 653.6M | 644.7M | 369.2M | 263.1M |
Balance Sheet Composition
HPC Biosciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 180.0M | 2.0M | -19.2M | -31.6M | 435.3M |
| Operating Cash Flow | -266.4M | -217.2M | -110.6M | -485.5M | -230.3M |
| Investing Activities | |||||
| Capital Expenditures | 3.4M | -43.8M | -131.2M | -572.3M | -9.1M |
| Investing Cash Flow | -11.7M | -43.8M | -129.3M | -572.3M | -8.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 323.3M | 631.0M | 431.6M | 844.5M | 151.8M |
| Free Cash Flow | -188.3M | -238.9M | -346.0M | -807.2M | -168.4M |
Cash Flow Trend
HPC Biosciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.40
Price to Book
2.73
Price to Sales
0.42
Profitability Ratios
Profit Margin
2.08%
Operating Margin
9.07%
Return on Equity
18.45%
Return on Assets
6.86%
Financial Health
Current Ratio
1.06
Debt to Equity
240.30
Beta
0.16
Per Share Data
EPS (TTM)
₹12.42
Book Value per Share
₹65.50
Revenue per Share
₹601.83
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| hpbl | 1.9B | 14.40 | 2.73 | 18.45% | 2.08% | 240.30 |
| Time Technoplast | 103.8B | 26.72 | 3.58 | 14.14% | 7.11% | 24.71 |
| EPL | 75.5B | 21.00 | 3.20 | 16.35% | 8.52% | 34.02 |
| Uflex Limited | 43.4B | 30.00 | 0.58 | 1.95% | 0.96% | 112.93 |
| TCPL Packaging | 34.1B | 23.86 | 5.30 | 24.46% | 8.08% | 101.18 |
| Cosmo First | 30.5B | 22.79 | 2.07 | 9.48% | 4.61% | 98.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.